You are here

Health Care & Law

How does the Patient Protection and Affordable Care Act (ACA) of 2010 differ from the act as it stands today? Many changes have occurred, in Medicaid expansion, private insurance coverage, the American Health Benefit Exchanges, and the individual mandate.
Patrick R. LaFontaine PharmD
F. Randy Vogenberg PhD, RPh
Laura T. Pizzi PharmD, MPH
As marijuana legalization and use expands across the U.S., health care systems are struggling to keep abreast of the changes and trends in regulations. Considering marijuana’s federal illegality and other restrictions on its use, the limited evidence for its clinical efficacy, and the myriad psychological adverse events, caution is recommended when establishing policies and procedures regarding coverage of marijuana and CBD products.
James O’Donnell PharmD, MS, FCP
F. Randy Vogenberg BSc Pharm, PhD
Increased cannabis use has brought about a sea change in policy and attitudes toward regulation, and a multitude of rules that vary widely between states. The disparity has stymied any effective response to the problems surrounding access to cannabis products for those in need. Health care providers and practitioners, as well as P&T committees, must carefully undertake decisions on rational drug use, whether or not their patients are using cannabis while under their care.
Rita Marcoux RPh, MBA
Lauren Holmes PharmD, MBA, MPH
F. Randy Vogenberg RPh, PhD
In the complex setting of obstetrics and reproductive medicine, the medication-related injuries leading to the most litigation involve some of the most commonly used drugs, rather than the newer, more complicated therapies. The authors present a number of cases illustrating how sophisticated treatment of high-risk pregnancies can be jeopardized by a simple negligent act.
James T. O’Donnell PharmD, MS, FCP
James J. O’Donnell PhD
F. Randy Vogenberg BSc Pharm, PhD

The authors underscore the importance of understanding standards and procedures as they discuss two lawsuits that arose from drug injury.

James T. O’Donnell PharmD, MS, FCP
F. Randy Vogenberg BSc Pharm, PhD

Despite a slow legislative start by President Trump, new federal and state regulatory health care changes will have important implications for pharmacists, P&T committees, and patients.

F. Randy Vogenberg BSc, PhD, RPh
Rita Marcoux BSc, MBA, RPh

Appropriate risk management strategies must be employed for compounding and administering sterile products. We review the new credentialing, regulatory, and related legal aspects of gaining and maintaining compliance for these processes.

Dawn G. Holcombe FACMPE, MBA, ACHE
Rita Marcoux RPh, MBA
F. Randy Vogenberg PhD, RPh

Over the past few years, P&T committees have been evolving to deal with care at expanding sites within an organization, across a larger system, or involving multiple organizations. The authors consider one aspect of this expansion—medication system failures—that requires the attention of P&T policy.

James T. O’Donnell PharmD, MS, FCP
F. Randy Vogenberg RPh, PhD
The HEAT Initiative Is Gaining Momentum

The pharmacy benefit management (PBM) industry has recently fallen into the crosshairs of government investigations about the high cost of pharmaceuticals. The authors focus on the PBM-based P&T and formulary practices under scrutiny.

Martha M. Rumore PharmD, JD, MS, LLM, FAPhA
F. Randy Vogenberg RPh, PhD

Telehealth is becoming mainstream in the U.S., as more consumers, employers, hospital systems, and even insurers adopt the technology. The authors explore the challenges of regulation, reimbursement, and licensing as the modality evolves.

Rita M. Marcoux RPh, MBA
F. Randy Vogenberg RPh, PhD